IIL will collaborate with Griffith University of Australia, a subsidiary of NDDB, to develop a research / coronary vaccine.

IIL will collaborate with Griffith University of Australia, a subsidiary of NDDB, to develop a research / coronary vaccine.

NDDB subsidiary IIL will collaborate with Griffith University in Australia to develop coronary vaccine

NDDB subsidiary IIL will collaborate with Griffith University in Australia to develop coronary vaccine
Scientists at IIL and Griffith University will develop vaccines using state-of-the-art technology
IIL is already working with Griffith University to research the vaccine for the Zika virus

Anand. Hyderabad-based Indian Immunologicals Limited (IIL), a wholly owned subsidiary of the National Dairy Development Board (NDDB), will collaborate with Griffith University, Australia to develop the coronavirus vaccine. Regarding this, Dilip Rath, chairman of NDDB and IIL, said that in this very important inter-continental collaboration, scientists from IIL and Griffith University will develop live-attenuated source - COV-2 vaccine-1 or Covi-Vodin19, using sophisticated codon de-optimization technology.

The vaccine is expected to provide long-term protection: IIL chairman Dilip Rath

IIL Chairman Dilip Rath added that the technology looks promising to develop an immunologically active, single-dose vaccine against coronavirus in humans with an enhanced safety profile. The vaccine is expected to provide long-term protection. Upon completion of this research, the vaccine strain will be brought to the IIL and the makers of the vaccine will work in accordance with the country's Director of Central Drugs Standard Control Organization (CDSCO) to conduct further medical tests, which will be carried out in a phased manner.

IIL A leading institution in veterinary biology

Rath said IIL is a leading institution in veterinary biology and is committed to meeting the critical needs of public health. The mission of IIL is to develop and supply a vaccine that supports the One Health Initiative. IIL is committed to developing affordable, high-quality vaccines. IIL is the largest manufacturer of foot and mouth vaccine vaccine worldwide and was the first in India to launch a Purified Vero Cell Rabies Vaccine for Humans (PVRV).

The vaccine will be a live attenuated vaccine

Talking about this research collaboration, Professor Suresh Mahalingam Menzies of Health Institute Queensland, Griffith University, Australia said that we are thrilled to work closely with IIL to develop this important vaccine. Since this vaccine is a live attenuated vaccine, it is expected to prove to be very effective in providing a highly potent cellular and antibody immune response to the virus. Another benefit of the live-attenuated vaccine is that it has a proven track record of mass production in an affordable way and is very prevalent in seeking regulatory approvals.

IIL works with Griffith University to vaccinate against the Zika virus

IIL is already working with Griffith University to conduct research and development on the Zika virus vaccine, which is currently undergoing pre-clinical toxicology testing. The codon de-optimization technology has been successfully employed to reduce the virulence of some RNA viruses, including Enterovirus C (poliovirus), human immunodeficiency virus type 1, Zika virus, etc.

Comments

Popular posts from this blog

[Cicket Update] MS Dhoni Retirement On International Cricket Match.

Corona LIVE Update Gujarat / New 7 positive cases reported at designated hotspots, 5 patients infected with exposure to positive cases,

It will be mandatory to link Aadhar and Water ID, the government is ready to implement the new rule 2020.